Abstract
Pulmonary veno-occlusive disease (PVOD) is a rare and devastating cause of pulmonary hypertension that is characterized histologically by widespread fibrous intimal proliferation of septal veins and preseptal venules and is frequently associated with pulmonary capillary dilatation and proliferation1,2. PVOD is categorized into a separate pulmonary arterial hypertension–related group in the current classification of pulmonary hypertension3. PVOD presents either sporadically or as familial cases with a seemingly recessive mode of transmission4. Using whole-exome sequencing, we detected recessive mutations in EIF2AK4 (also called GCN2) that cosegregated with PVOD in all 13 families studied. We also found biallelic EIF2AK4 mutations in 5 of 20 histologically confirmed sporadic cases of PVOD. All mutations, either in a homozygous or compound-heterozygous state, disrupted the function of the gene. These findings point to EIF2AK4 as the major gene that is linked to PVOD development and contribute toward an understanding of the complex genetic architecture of pulmonary hypertension.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Pulmonary veno-occlusive disease in Sjogren's syndrome: a case report
BMC Pulmonary Medicine Open Access 18 January 2023
-
A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease
BMC Pulmonary Medicine Open Access 30 November 2022
-
New progress in diagnosis and treatment of pulmonary arterial hypertension
Journal of Cardiothoracic Surgery Open Access 29 August 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout



Accession codes
References
Mandel, J., Mark, E.J. & Hales, C.A. Pulmonary veno-occlusive disease. Am. J. Respir. Crit. Care Med. 162, 1964–1973 (2000).
Montani, D. et al. Pulmonary veno-occlusive disease. Eur. Respir. J. 33, 189–200 (2009).
Simonneau, G. et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 54, S43–S54 (2009).
Davies, P. & Reid, L. Pulmonary veno-occlusive disease in siblings: case reports and morphometric study. Hum. Pathol. 13, 911–915 (1982).
Heath, D., Segel, N. & Bishop, J. Pulmonary veno-occlusive disease. Circulation 34, 242–248 (1966).
Montani, D. et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine 87, 220–233 (2008).
Trembath, R.C. et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N. Engl. J. Med. 345, 325–334 (2001).
Girerd, B. et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am. J. Respir. Crit. Care Med. 181, 851–861 (2010).
Machado, R.D. et al. Genetics and genomics of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54, S32–S42 (2009).
Rosenthal, A., Vawter, G. & Wagenvoort, C.A. Intrapulmonary veno-occlusive disease. Am. J. Cardiol. 31, 78–83 (1973).
Voordes, C.G., Kuipers, J.R. & Elema, J.D. Familial pulmonary veno-occlusive disease: a case report. Thorax 32, 763–766 (1977).
Larkin, E.K. et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 186, 892–896 (2012).
Humbert, M. et al. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am. J. Respir. Crit. Care Med. 157, 1681–1685 (1998).
Langleben, D. et al. Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. Ann. Intern. Med. 109, 106–109 (1988).
Lantuéjoul, S., Sheppard, M.N., Corrin, B., Burke, M.M. & Nicholson, A.G. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am. J. Surg. Pathol. 30, 850–857 (2006).
Donnelly, N., Gorman, A.M., Gupta, S. & Samali, A. The eIF2α kinases: their structures and functions. Cell. Mol. Life Sci. 70, 3493–3511 (2013).
Anthony, T.G. et al. Preservation of liver protein synthesis during dietary leucine deprivation occurs at the expense of skeletal muscle mass in mice deleted for eIF2 kinase GCN2. J. Biol. Chem. 279, 36553–36561 (2004).
Chaveroux, C. et al. Identification of GCN2 as new redox regulator for oxidative stress prevention in vivo. Biochem. Biophys. Res. Commun. 415, 120–124 (2011).
Fessel, J.P. et al. Hyperoxia synergizes with mutant BMPR2 to cause metabolic stress, oxidant injury, and pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 49, 778–787 (2013).
Machado, R.D. et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am. J. Hum. Genet. 68, 92–102 (2001).
Barrios-Rodiles, M. et al. High-throughput mapping of a dynamic signaling network in mammalian cells. Science 307, 1621–1625 (2005).
Carraro, V. et al. Amino acid availability controls TRB3 transcription in liver through the GCN2/eIF2α/ATF4 pathway. PLoS ONE 5, e15716 (2010).
Chan, M.C. et al. A novel regulatory mechanism of the bone morphogenetic protein (BMP) signaling pathway involving the carboxyl-terminal tail domain of BMP type II receptor. Mol. Cell. Biol. 27, 5776–5789 (2007).
Davies, R.J. et al. BMP type II receptor deficiency confers resistance to growth inhibition by TGF-β in pulmonary artery smooth muscle cells: role of proinflammatory cytokines. Am. J. Physiol. Lung Cell. Mol. Physiol. 302, L604–L615 (2012).
Sattlegger, E. & Hinnebusch, A.G. Separate domains in GCN1 for binding protein kinase GCN2 and ribosomes are required for GCN2 activation in amino acid–starved cells. EMBO J. 19, 6622–6633 (2000).
Humbert, M. et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 173, 1023–1030 (2006).
Sitbon, O. et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111, 3105–3111 (2005).
Sztrymf, B. et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am. J. Respir. Crit. Care Med. 177, 1377–1383 (2008).
Eyries, M. et al. ACVRL1 germinal mosaic with two mutant alleles in hereditary hemorrhagic telangiectasia associated with pulmonary arterial hypertension. Clin. Genet. 82, 173–179 (2012).
O'Connell, J.R. & Weeks, D.E. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am. J. Hum. Genet. 63, 259–266 (1998).
Abecasis, G.R., Cherny, S.S., Cookson, W.O. & Cardon, L.R. Merlin—rapid analysis of dense genetic maps using sparse gene flow trees. Nat. Genet. 30, 97–101 (2002).
Kong, A. & Cox, N.J. Allele-sharing models: LOD scores and accurate linkage tests. Am. J. Hum. Genet. 61, 1179–1188 (1997).
Barrett, J.C., Fry, B., Maller, J. & Daly, M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263–265 (2005).
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
Acknowledgements
We thank F. Pires, A. Dion-Minière, S. Bakas, G. Legrand and N. Raymond for technical assistance. We thank W. Carpentier for supervising SNP array experiments. We thank R. Peat for kindly editing the manuscript. D.M. and P.D. are supported by a grant from the Association Hypertension Artérielle Pulmonaire (HTAP) France. This work was supported by Programme Hospitalier de Recherche Clinique (PHRC) AOM07-041, INSERM and UPMC. The tissue bank was supported in part by the Legs Poix, Chancellerie des Universités de Paris. Bioinformatics analyses benefit from the C2BIG computing centre funded by the Région Ile de France and UPMC.
Author information
Authors and Affiliations
Contributions
F.S. initiated and supervised the study. M.E., D.-A.T., M.H. and F.S. conceived and designed the experiments. D.M., B.G., D.B., O.S., G.S., E.F. and M.H. performed clinical phenotyping. D.M., B.G. and M.H. analyzed clinical data of collected patients. C.P. performed the whole-exome sequencing experiments. N.C. performed bioinformatic analyses. D.-A.T. supervised bioinformatic and biostatistical data. M.E. and F.S. analyzed whole-exome sequencing data. C.L. performed linkage analysis. A.L. performed Sanger sequencing. M.E. and F.C. analyzed Sanger sequencing data. E.F. collected lung sample specimens. P.D. performed tissue imaging. M.E., D.M., B.G., D.-A.T., M.H. and F.S. wrote the manuscript. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–3 and Supplementary Tables 1–4 (PDF 1247 kb)
Rights and permissions
About this article
Cite this article
Eyries, M., Montani, D., Girerd, B. et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 46, 65–69 (2014). https://doi.org/10.1038/ng.2844
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.2844
This article is cited by
-
Pulmonary veno-occlusive disease in Sjogren's syndrome: a case report
BMC Pulmonary Medicine (2023)
-
A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease
BMC Pulmonary Medicine (2022)
-
New progress in diagnosis and treatment of pulmonary arterial hypertension
Journal of Cardiothoracic Surgery (2022)
-
A non-canonical cGAS–STING–PERK pathway facilitates the translational program critical for senescence and organ fibrosis
Nature Cell Biology (2022)
-
Identification of a Novel EIF2AK Variant and Genetics-Assisted Approach to Diagnosis of Pulmonary Capillary Hemangiomatosis
Lung (2022)